Bayer inks $290M collaboration deal with Ortho-McNeil

Bayer Healthcare has struck a $290 million deal to develop a new drug for blood clots with Johnson & Johnson. Bay 59-7939 is set to begin late-stage trials in the next few weeks. J&J's Ortho-McNeil will make an upfront payment and share in the global development costs of the drug.

- read this AP article for more

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.